Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2006 Jan 1;16(1):108-12. Epub 2005 Oct 19.

Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.

Author information

1
Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland. rudolf.waelchli@novartis.com

Abstract

The design, synthesis, and the biological evaluation of 2-benzamido-pyrimidines as novel IKK inhibitors are described. By optimization of the lead compound 3, compounds 16 and 24 are identified as good inhibitors of IKK2 with IC(50) values of 40 and 25 nM, respectively. Compound 16 also demonstrated significant in vivo activity in an acute model of cytokine release.

PMID:
16236504
DOI:
10.1016/j.bmcl.2005.09.035
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center